On January 11th, 2020, scientists around the globe awoke to the public deposition of the entire genome for the novel coronavirus – later known as SARS-CoV-2. That weekend, researchers at the University of Texas at Austin designed a vaccine based on the SARS-CoV-2 spike protein, which adorns the surface of the virus. Just two weeks later, scientists at the NIH's Vaccine Research Center started testing the vaccine in animals. This initial design was licensed for use in the first three FDA-approved COVID-19 vaccines. Many contributing factors lead to the expediency of this vaccine design, none of which compromised safety. But how could we rapidly develop a vaccine for a novel virus while other viral targets have remained elusive?... Click the image to the left to continue reading.

Dr. Newcomb earned her undergraduate degree from North Carolina State University in 2002 and her Ph.D. from University of Michigan in 2007. She trained as a post-doctoral fellow in Dr. R. Stokes Peebles, Jr. M.D. laboratory at Vanderbilt University focusing on lung inflammation, viral infections, and T cell immune responses. In 2014, Dr. Newcomb started her laboratory at Vanderbilt to study how sex hormones regulate mechanisms of airway inflammation in asthma. Dr. Newcomb currently has 2 R01s to study these mechanisms...... Click Dr. Newcomb's photo to continue reading.

The gut microbiota is associated with immune cell dynamics in humans. Schluter J, et al. in Nature, December 1, 2020 Rapid transcriptional and metabolic adaptation of intestinal microbes to host immune activation. Becattini S, et al.

Most of the vaccines that protect us from viruses do so by stimulating your body to produce antibodies. Antibodies are y-shaped proteins that circulate in the blood and recognize and fight off pathogens such as viruses. Immune cells called B cells recognize the pathogens and make a range of antibodies in response to an infection.... Click the infographic to learn more!

Coronavirus terminology can be confusing. You may see the terms SARS-CoV-2, COVID-19, and coronavirus used interchangeably, but these words don't mean the same thing. Coronavirus refers to an entire family of viruses. They were named coronaviruses because, under a microscope, protrusions on the virus surface resemble a crown (or corona). Many coronaviruses cause mild, cold-like symptoms, and we may have been infected with them before unknowingly.... Click the infographic to learn more!

Viruses are remarkably simple for how much devastation they cause. SARS-CoV-2 is composed of a ball of protein and lipids (or fats) that contains genetic material (or RNA) inside. Different vaccine approaches either use parts of the virus (e.g., the genetic material or proteins) or the whole virus to generate an immune response to fight the infection.... Click the infographic to learn more!

The mRNA vaccine is a new type of vaccine that allows your body to trigger an immune response without using the actual germ to train your immune system. Instead, it trains your immune response using a piece of the virus and will later protect you from getting infected/sick if you encounter the actual virus. Since it is new, here is a list of the generalized ingredients for the mRNA vaccines currently available in the US.... Click the infographic to learn more!

Jonathan is a graduate student in the Lars Plate lab. He chose the Plate lab because of the interdisciplinary proteomics and chemical biology approaches they were using to study viruses and because of the outstanding training environment Lars and group members provided. His project combines chemical biology tools with quantitative mass spectrometry methods to map host-virus interactomics with temporal resolution during infection, with the aim of identifying potential host factors as therapeutic targets to combat viral pathogenesis... Click the image on the left to continue reading.

Wenhan Zhu received his Ph.D. at Purdue University in Biological Sciences and is an Assistant Professor in Pathology, Microbiology, and Immunology. In his lab, they focus on the metabolic interactions that dictate the changes or resilience of the microbiota. Insight into such interactions could enable precise manipulation of gut microbiota composition, thus restoring a balanced community in situ and improving host health. To precisely manipulate the microbiota, they use a multidisciplinary discovery pipeline that consists of next-generation sequencing, bacterial genetics and a mechanistic understanding of bacterial physiology in vivo. This pipeline allows them to discover druggable targets of the microbiota and translate the findings using high-throughput screening.... Click Dr. Zhu's photo to continue reading.